Filter Specialty
Filterspecialty
Submit To The Journals
Previous
Article
Next
Article

Antihyperglycemic Medications and Cardiovascular Risk Reduction

European Endocrinology, 2017;13(2):86–90 DOI: https://doi.org/10.17925/EE.2017.13.02.86

Abstract

Cardiovascular disease (CVD) remains a leading cause of death in patients with type 2 diabetes (T2D). In addition to glycemic control, a major focus of diabetes treatment involves cardiovascular (CV) risk reduction. In 2008, the US Food and Drug Administration (FDA) instituted a new requirement that new drugs developed and studied for the treatment of T2D must undergo CV safety testing. Since the advent of this new policy, canagliflozin, empagliflozin, liraglutide and semaglutide have demonstrated superior CV event reduction – via a composite of reduction in CV death, nonfatal myocardial infarction (MI), and nonfatal stroke – compared with placebo in patients with T2D and existing CVD, or at high risk of CVD. Multiple studies are underway to evaluate the CV outcomes of other antihyperglycemic agents. In a time when there are numerous drugs in the T2D armamentarium, positive CV outcomes data influence drug selection and aids practitioners in making more individualised therapeutic recommendations for their patients.

Keywords

Diabetes, cardiovascular disease, antihyperglycemic, glucagon-like peptide-1 receptor agonists (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors

Disclosure

Sarah L Anderson and Joel C Marrs have nothing to declare in relation to this article. No funding was received in the publication of this article. This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Open Access

This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.

Accepted

2017-05-25T00:00:00

Published Online

July 13, 2017

Correspondence

Sarah L Anderson; Mail Stop C238, 12850 E. Montview Blvd., room V20-2129, Aurora, Colorado, 80045, US. E: Sarah.Anderson@ucdenver.edu

  • Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. © 2019 All rights reserved.

    touchendocrinology is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.